It depends on which specific hormones were studied, not on hormone therapy as one single thing.

The 2002 trial that raised the alarm tested one particular regimen: oral conjugated equine estrogens (Premarin) combined with a synthetic progestin, medroxyprogesterone acetate (Provera). That combination showed a modest increase in breast cancer, about 8 additional cases per 10,000 women per year, and the increase became more statistically clear with longer follow-up. The parallel arm of the same trial, the same oral estrogen alone in women without a uterus, found the opposite: lower breast cancer incidence and lower breast cancer death, sustained over 20 years. Neither arm tested the combination most commonly prescribed today, transdermal estradiol with micronized progesterone; no dedicated randomized trial has ever measured its breast cancer risk. So "hormones cause breast cancer" is too simple a statement: the molecule, the route, and the specific combination all matter, and the exact regimen many women take now has never itself been tested for this outcome.

What to know about this answer

Both sides in this debate accept that combined therapy raised breast cancer diagnoses in the WHI trial; the real dispute is over how large and clinically meaningful that increase is, and whether it applies to modern, non-oral regimens.

What the research shows, and which source each finding rests on

The original 2002 WHI trial found a breast cancer hazard ratio of 1.26 for combined estrogen-progestin therapy, with a confidence interval that touched 1.00, and an absolute excess of 8 additional invasive breast cancers per 10,000 women per year.

B[1]

At more than 20 years of cumulative follow-up, combined therapy breast cancer incidence was HR 1.28, while the parallel estrogen-alone trial showed lower invasive breast cancer incidence (HR 0.78) and lower breast cancer mortality (HR 0.60).

B[2]B[3]

Neither WHI regimen changed all-cause mortality over 18 years of cumulative follow-up.

B[4]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

the original result was overstated and should be read with its absolute numbers

Sharon Malone, Avrum Bluming, Mary Claire Haver, Kelly Casperson

The 2002 confidence interval touched 1.0, there was no excess breast cancer mortality at the time, and all-cause mortality was never affected across 18 years of follow-up; framed in absolute terms, it was fewer than one extra case per 1,000 women per year.

B[1]B[4]

the result was real and became clearer, not weaker, over time

the WHI investigators (Chlebowski, Manson, Anderson)

Invasive breast cancer was the trial's prespecified primary safety outcome, and with 20-plus years of follow-up the combined-therapy incidence increase became statistically unambiguous, with cancers also more often node-positive.

B[2]

What would settle it: The incidence excess with combined estrogen-progestin therapy is not seriously disputed by either side; the open questions are its magnitude, its relevance to death rather than diagnosis, and whether it applies to modern transdermal and micronized-progesterone regimens, which no dedicated trial has tested.

What is really going on here

  1. Tell me my risk in absolute numbers, per 1,000 women like me per year, not as a percentage increase.
  2. Which regimen are we discussing, and is it the same one the original trial studied?
  3. Do I have a uterus? If not, why would the combined-therapy numbers apply to me at all?

Questions for your doctor

  1. What is my absolute added risk, in real numbers, on the specific regimen you're proposing?
  2. Is combined therapy necessary for me, or could an estrogen-only approach apply given my history?
  3. How does my personal risk profile (family history, breast density, prior biopsies) factor into this?
  4. How often will we reassess this decision?

Questions with no answer yet

Would a modern, non-oral regimen, transdermal estradiol with micronized progesterone, show the same breast cancer signal as the oral estrogen-plus-synthetic-progestin regimen studied in the original trial?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: No dedicated randomized trial with breast cancer as an endpoint has ever tested transdermal estradiol combined with micronized progesterone. The only randomized breast cancer data comes from the older oral regimens.

What would test it: A randomized trial of the modern regimen with breast cancer incidence as a prespecified endpoint, or at minimum a large linked-registry study with detailed regimen-level exposure data.

Is the estrogen-alone protective effect on breast cancer a real, generalizable biological effect, or specific to the older, hysterectomized, heavier trial population it was found in?

Partly studied

What is known: The randomized estrogen-alone trial found lower breast cancer incidence and mortality over 20-plus years, but the trial authors themselves caution the finding does not support using estrogen specifically to lower breast cancer risk, since the benefit concentrated in women without benign breast disease or family history, and large observational data point the other way with longer duration.

What would test it: Dose-timing studies of estradiol, rather than the specific conjugated equine estrogen used in the original trial, started early in menopause with breast cancer endpoints prespecified.

Sources

  1. 1.Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.Writing Group for the WHI Investigators (Rossouw JE et al.), JAMA 2002 · Randomised trial
  2. 2.Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.Chlebowski RT et al., JAMA 2020 · Randomised trial
  3. 3.Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial.Anderson GL et al., Lancet Oncol 2012 · Randomised trial
  4. 4.Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials.Manson JE et al., JAMA 2017 · Randomised trial

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides